Drugs / TISA-818-Inj
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07337044 | Jan → Oct 2024 | — | EnliTISA (Shanghai) Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TISA-818-Inj | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07337044 ↗ |
| Route | Subcutaneous | “after single and multiple s.c. injections in healthy subjects” NCT07337044 ↗ |